DPPC、DSPE-PEG2000和胆固醇参与制备纳米增敏剂
瑞禧生物2025-02-12   作者:ZJ   来源:
字号大小:

文献:Checkpoint blockade and nanosonosensitizeraugmented noninvasive sonodynamic theapy combination reduces tumour growth and metastases in mice

文献链接:https://xueshu.baidu.com/usercenter/paper/show?paperid=1b2r0j40t81708b0t56x0v30bk152020&site=xueshu_se

作者:Wenwen Yue, Liang Chen, Luodan Yu, Bangguo Zhou, Haohao Yin, Weiwei Ren, Chang Liu,

Lehang Guo, Yifeng Zhang, Liping Sun, Kun Zhang , Huixiong Xu& Yu Chen

相关产品:

Cholesterol 胆固醇

Cy5.5-DSPE-PEG 花菁染料cy5.5-二硬脂酰基磷脂酰乙醇胺-聚乙二醇

DSPE-PEG2000 二硬脂酰基磷脂酰乙醇胺-聚乙二醇2000

DPPC 二棕榈酰磷脂酰胆碱

原文摘要:Combined checkpoint blockade (e.g., PD1/PD-L1) with traditional clinical therapies can be hampered by side effects and low tumour-therapeutic outcome, hindering broad clinical

translation. Here we report a combined tumour-therapeutic modality based on integrating

nanosonosensitizers-augmented noninvasive sonodynamic therapy (SDT) with checkpointblockade immunotherapy. All components of the nanosonosensitizers (HMME/R837@Lip)are clinically approved, wherein liposomes act as carriers to co-encapsulate sonosensitizers(hematoporphyrin monomethyl ether (HMME)) and immune adjuvant (imiquimod (R837)).Using multiple tumour models, we demonstrate that combining

nanosonosensitizersaugmented SDT with anti-PD-L1 induces an anti-tumour response, which not only arrestsprimary tumour progression, but also prevents lung metastasis. Furthermore, the combinedtreatment strategy offers a long-term immunological memory function, which can protectagainst tumour rechallenge after elimination of the initial tumours. Therefore, this work

represents a proof-of-concept combinatorial tumour therapeutics based on noninvasive

tumours-therapeutic modality with immunotherapy.

 

DSPE-PEG2000 由二硬脂酰磷脂酰乙醇胺(DSPE)和聚乙二醇(PEG)2000 组成。DSPE 部分具有亲脂性,能够与脂质膜良好结合,而 PEG2000 则具有亲水性和良好的生物相容性。

它可以用于修饰脂质体、纳米颗粒等化合物载体,提高载体的稳定性和体内循环时间。通过 DSPE-PEG2000 的修饰,化合物载体能够有效地躲避免疫系统的识别和清除,从而促使化合物靶向输送。此外,它还可以用于制备生物传感器和分子成像探针。基于此建立了与SDT、增强SDT免疫和抗pd-l1相结合的策略,构建的免疫佐剂和声增敏剂共载纳米脂质体作为纳米增敏剂成功实现。以下是制备方法:

DPPC、DSPE-PEG2000和胆固醇参与制备纳米增敏剂 

图:HMME/R837@Lip纳米纳米增敏剂及其微结构的构建示意图;

HMME/R837@唇状纳米增敏剂的制备。

HMME/R837@Lip采用典型的反蒸发法合成。R837和HMME首先分别溶解在DMSO(和甲醇中。然后,将R837和HMME溶液依次加入含有DPPC、DSPE-PEG2000和胆固醇的三氯甲烷溶液中,按照一定重量比。在旋转蒸发器上进行蒸发。然后,将压力降低到0 mbar,旋转混合物蒸发过夜,以完全去除溶剂,得到脂质薄膜。然后,在脂膜中加入PBS,在油浴中再旋转。最终,通过分别使用200-和100nm膜的微型挤压过程获得囊泡,然后通过透析进一步纯化。

 DPPC、DSPE-PEG2000和胆固醇参与制备纳米增敏剂 

图:不同处理后用DCFH-DA染色的4T1细胞的CLSM图像,HMME@Lip联合美国照射和HMME/R837@Lip联合美国照射(比例尺= 20 μm);

 

结论:在DPPC、DSPE-PEG2000和胆固醇参与制备的HMME/ R837@Lip的紫外-可见吸收光谱中,HMME在~398 nm处有一个明显的特征吸收峰,表明HMME成功封装成纳米颗粒,这也可以通过从HMME@Lip的Zeta电位变化和高效液相色谱(HPLC)结果来验证。HPLC进一步证实了R837的成功共加载,以及从HMME@Lip到HMME/R837@Lip的表面Zeta电位的增加。HMME/R837@Lip中HMME和R837的加载效率和容量都是可控的,且随初始饲喂浓度的不同而变化。